NO20042839L - Farmasoytiske kombinasjoner av adenosin A-2A og beta-2-adrenerge reseptoragonister - Google Patents

Farmasoytiske kombinasjoner av adenosin A-2A og beta-2-adrenerge reseptoragonister

Info

Publication number
NO20042839L
NO20042839L NO20042839A NO20042839A NO20042839L NO 20042839 L NO20042839 L NO 20042839L NO 20042839 A NO20042839 A NO 20042839A NO 20042839 A NO20042839 A NO 20042839A NO 20042839 L NO20042839 L NO 20042839L
Authority
NO
Norway
Prior art keywords
adenosine
beta
receptor agonists
adrenergic receptor
pharmaceutical combinations
Prior art date
Application number
NO20042839A
Other languages
English (en)
Norwegian (no)
Inventor
Michael Yeaden
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20042839L publication Critical patent/NO20042839L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
NO20042839A 2001-12-06 2004-07-05 Farmasoytiske kombinasjoner av adenosin A-2A og beta-2-adrenerge reseptoragonister NO20042839L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129270.5A GB0129270D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination
PCT/IB2002/005057 WO2003047598A1 (en) 2001-12-06 2002-11-28 Pharmaceutical combinations of adenosine a-2a and beta-2-adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
NO20042839L true NO20042839L (no) 2004-07-05

Family

ID=9927164

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042839A NO20042839L (no) 2001-12-06 2004-07-05 Farmasoytiske kombinasjoner av adenosin A-2A og beta-2-adrenerge reseptoragonister

Country Status (37)

Country Link
EP (1) EP1455799B1 (ko)
JP (1) JP2005513041A (ko)
KR (1) KR100685557B1 (ko)
CN (1) CN1856314A (ko)
AP (2) AP2004003082A0 (ko)
AR (1) AR037634A1 (ko)
AT (1) ATE293982T1 (ko)
AU (1) AU2002351066B2 (ko)
BR (1) BR0214998A (ko)
CA (1) CA2469085A1 (ko)
CO (1) CO5580752A2 (ko)
DE (1) DE60203934T2 (ko)
DK (1) DK1455799T3 (ko)
EA (1) EA200400639A1 (ko)
EC (1) ECSP045132A (ko)
ES (1) ES2239728T3 (ko)
GB (1) GB0129270D0 (ko)
GT (1) GT200200258A (ko)
HN (1) HN2002000348A (ko)
HR (1) HRP20040517A2 (ko)
HU (1) HUP0402540A3 (ko)
IS (1) IS7280A (ko)
MA (1) MA27150A1 (ko)
MX (1) MXPA04005506A (ko)
NO (1) NO20042839L (ko)
NZ (1) NZ533054A (ko)
OA (1) OA12738A (ko)
PA (1) PA8560701A1 (ko)
PE (1) PE20030834A1 (ko)
PL (1) PL370739A1 (ko)
PT (1) PT1455799E (ko)
SV (1) SV2004001426A (ko)
TN (1) TNSN04101A1 (ko)
TW (1) TWI256388B (ko)
UY (1) UY27566A1 (ko)
WO (1) WO2003047598A1 (ko)
ZA (1) ZA200403966B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785969B1 (ko) * 2004-05-12 2007-12-14 동아제약주식회사 Fgf2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク. 乾燥粉末配合および使用方法
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
WO2022050230A1 (ja) * 2020-09-03 2022-03-10 学校法人埼玉医科大学 アデノシン受容体の活性化を抑制する組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives

Also Published As

Publication number Publication date
ZA200403966B (en) 2005-06-22
TWI256388B (en) 2006-06-11
PA8560701A1 (es) 2004-05-07
ATE293982T1 (de) 2005-05-15
DE60203934D1 (de) 2005-06-02
DE60203934T2 (de) 2006-02-23
EA200400639A1 (ru) 2004-12-30
HUP0402540A2 (hu) 2005-07-28
KR20050044697A (ko) 2005-05-12
MXPA04005506A (es) 2004-12-10
MA27150A1 (fr) 2005-01-03
UY27566A1 (es) 2003-07-31
EP1455799B1 (en) 2005-04-27
GT200200258A (es) 2003-08-22
AU2002351066B2 (en) 2007-10-18
AP2004003053A0 (en) 2004-06-30
PT1455799E (pt) 2005-08-31
HRP20040517A2 (en) 2004-10-31
CO5580752A2 (es) 2005-11-30
TW200300759A (en) 2003-06-16
EP1455799A1 (en) 2004-09-15
NZ533054A (en) 2007-02-23
KR100685557B1 (ko) 2007-02-22
DK1455799T3 (da) 2005-06-27
PE20030834A1 (es) 2003-10-08
ECSP045132A (es) 2004-07-23
OA12738A (en) 2006-06-29
WO2003047598A1 (en) 2003-06-12
IS7280A (is) 2004-05-21
GB0129270D0 (en) 2002-01-23
TNSN04101A1 (fr) 2006-06-01
CN1856314A (zh) 2006-11-01
AR037634A1 (es) 2004-11-17
JP2005513041A (ja) 2005-05-12
AP2004003082A0 (en) 2004-09-30
BR0214998A (pt) 2004-12-28
AU2002351066A1 (en) 2003-06-17
ES2239728T3 (es) 2005-10-01
PL370739A1 (en) 2005-05-30
CA2469085A1 (en) 2003-06-12
HUP0402540A3 (en) 2008-04-28
SV2004001426A (es) 2004-05-07
HN2002000348A (es) 2005-02-04

Similar Documents

Publication Publication Date Title
NO20035202D0 (no) En adenosin A2A reseptoragonist og et antikolinergmiddel i kombinasjon forbehandling av obstruktive luftveissykdommer
ATE453647T1 (de) Adenosin a2a rezeptor antagonisten
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
DK1283839T3 (da) Adenosin A2a-receptorantagonister
NO20041817L (no) Arylanilin beta-2-adrenergisk reseptoragonister
NO20051493L (no) Imidazolpyridiner og fremgangsmater for fremstilling og anvendelse av de samme
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1379224T3 (da) Guanylat-cyclase receptor-agonister til behandling af vævsinflammation og carciogenese
DK1056445T3 (da) Oralt administrerbar immediate-release- og prolinged-release- galenisk form omfattende et absorpsionsfremmende middel og anvendelse af dette absorpsionsfremmende middel
DK1206281T3 (da) Formulering indeholdende moxifloxacin og natriumchlorid
NO20012013D0 (no) 5HT1 reseptor agonister og metoclopramid for behandling av migrene
NO20043907L (no) Partielle og fullstendige agonister av A1-adenosinreseptorer
ATE358130T1 (de) Bicyclische (1,2,4ö-triazol adenosin a2a rezeptor antagonisten
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
PT1208100E (pt) Antagonistas selectivos de receptores de adenosina a2b
NO20042272L (no) Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister
NO20042839L (no) Farmasoytiske kombinasjoner av adenosin A-2A og beta-2-adrenerge reseptoragonister
NO20015659L (no) Purinderivater, fremstillingsmetode og farmasöytiske preparater inneholdende disse
NO20035300D0 (no) Aminokinolin- og aminopyridinderivater og deres anvendelse som adenosin A<N>3-ligander
NO20033506L (no) Parasitticidale preparater og metoder for anvendelse
IL127947A0 (en) Pharmaceutical use of adenosine agonists
NO20023144D0 (no) Kompleks omfattende OCIF og polysakkarid
ATE250621T1 (de) Oral aktive a1 adenosin rezeptor agonisten
ITMI20022518A1 (it) Dispositivo e procedimento per minimizzare ritardo di
NO20034172L (no) Bisykliske guanidinderivater og terapeutiske anvendelser derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application